EA201890894A1 - Комбинированная терапия - Google Patents

Комбинированная терапия

Info

Publication number
EA201890894A1
EA201890894A1 EA201890894A EA201890894A EA201890894A1 EA 201890894 A1 EA201890894 A1 EA 201890894A1 EA 201890894 A EA201890894 A EA 201890894A EA 201890894 A EA201890894 A EA 201890894A EA 201890894 A1 EA201890894 A1 EA 201890894A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alaninyl
phosphate
combined therapy
phenylbenzoxy
dicycloplatin
Prior art date
Application number
EA201890894A
Other languages
English (en)
Other versions
EA037248B1 (ru
Inventor
Хью Гриффит
Original Assignee
НУКАНА ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by НУКАНА ПиЭлСи filed Critical НУКАНА ПиЭлСи
Publication of EA201890894A1 publication Critical patent/EA201890894A1/ru
Publication of EA037248B1 publication Critical patent/EA037248B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Настоящее изобретение относится к комбинации гемцитабин[фенилбензокси-L-аланинил)]фосфата (химическое название: 2'-дезокси-2',2'-дифтор-D-цитидин-5'-O-[фенил(бензокси-L-аланинил)]фосфат) (NUC-1031) и противоракового средства на основе платины, выбранного из карбоплатина, дициклоплатина, оксалиплатина, сатраплатина и недаплатина. Комбинации могут использоваться для лечения злокачественного новообразования и, в частности, рака яичников.
EA201890894A 2015-10-05 2015-10-05 Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином EA037248B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/052902 WO2017060661A1 (en) 2015-10-05 2015-10-05 Combination therapy

Publications (2)

Publication Number Publication Date
EA201890894A1 true EA201890894A1 (ru) 2018-09-28
EA037248B1 EA037248B1 (ru) 2021-02-26

Family

ID=54330789

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890894A EA037248B1 (ru) 2015-10-05 2015-10-05 Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином

Country Status (12)

Country Link
US (3) US10660912B2 (ru)
EP (1) EP3359163B1 (ru)
JP (2) JP7038653B2 (ru)
KR (1) KR20180063075A (ru)
CN (1) CN108135920A (ru)
AU (1) AU2015411525B2 (ru)
CA (1) CA2994502C (ru)
EA (1) EA037248B1 (ru)
IL (1) IL257976A (ru)
MX (1) MX2018004137A (ru)
PH (1) PH12018500691A1 (ru)
WO (1) WO2017060661A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ES2725491T3 (es) 2012-11-16 2019-09-24 Univ College Cardiff Consultants Ltd Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato
LT3160978T (lt) 2014-06-25 2020-08-25 NuCana plc Gemcitabino provaistai
MY186584A (en) 2014-06-25 2021-07-28 Nucana Biomed Ltd Formulation comprising a gemcitabine-prodrug
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
SI3386998T1 (sl) 2015-12-11 2022-02-28 NuCana plc Diastereoselektivna sinteza fosfatnih derivatov in predzdravila gemcitabina NUC-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
PT3393478T (pt) * 2015-12-23 2020-03-24 NuCana plc Terapia combinada
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713914D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy
CA3082295A1 (en) * 2017-11-21 2019-05-31 Medoncare Pharmaceutical Co., Ltd Combination products containing dicycloplatin, preparation and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1011788A (en) 1909-09-01 1911-12-12 Colonial Trust Co Rotary motor.
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
CN1646534A (zh) 2002-02-14 2005-07-27 法玛塞特有限公司 修饰的氟化核苷类似物
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1740170A2 (en) * 2004-03-23 2007-01-10 AstraZeneca AB Combination therapy with azd2171 and platinum anti-tumour agent
SI2200431T1 (sl) 2007-09-10 2016-10-28 Boston Biomedical, Inc. Sestave in metode za zdravljenje raka
FR2954310B1 (fr) 2009-12-18 2014-07-25 Univ Rouen Procede de dedoublement d'enantiomeres par evapocristallisation preferentielle
UY33310A (es) 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
JP6255346B2 (ja) * 2011-10-20 2017-12-27 ネリウム バイオテクノロジー，インコーポレーテッド 癌治療のための治療用組合せ
ES2725491T3 (es) 2012-11-16 2019-09-24 Univ College Cardiff Consultants Ltd Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato
WO2015081133A2 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
LT3160978T (lt) 2014-06-25 2020-08-25 NuCana plc Gemcitabino provaistai
MY186584A (en) 2014-06-25 2021-07-28 Nucana Biomed Ltd Formulation comprising a gemcitabine-prodrug
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
WO2016181093A1 (en) 2015-05-14 2016-11-17 Nucana Biomed Limited Cancer treatments
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
SI3386998T1 (sl) 2015-12-11 2022-02-28 NuCana plc Diastereoselektivna sinteza fosfatnih derivatov in predzdravila gemcitabina NUC-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
PT3393478T (pt) 2015-12-23 2020-03-24 NuCana plc Terapia combinada
US20190381084A1 (en) 2015-12-23 2019-12-19 Nucana Biomed Limited Combination therapy

Also Published As

Publication number Publication date
KR20180063075A (ko) 2018-06-11
BR112018006880A2 (pt) 2018-10-16
CA2994502A1 (en) 2017-04-13
CA2994502C (en) 2023-08-01
AU2015411525A1 (en) 2018-03-15
US20220323475A1 (en) 2022-10-13
US20200268783A1 (en) 2020-08-27
WO2017060661A1 (en) 2017-04-13
IL257976A (en) 2018-05-31
MX2018004137A (es) 2018-06-13
US20180271889A1 (en) 2018-09-27
JP2022001599A (ja) 2022-01-06
AU2015411525B2 (en) 2021-08-12
PH12018500691A1 (en) 2018-10-15
JP2018529740A (ja) 2018-10-11
EP3359163A1 (en) 2018-08-15
CN108135920A (zh) 2018-06-08
EP3359163B1 (en) 2023-12-20
JP7038653B2 (ja) 2022-03-18
US10660912B2 (en) 2020-05-26
EA037248B1 (ru) 2021-02-26

Similar Documents

Publication Publication Date Title
EA201890894A1 (ru) Комбинированная терапия
EA201891473A1 (ru) Комбинированная терапия
EA201792169A1 (ru) 5'-замещенные нуклеозидные соединения
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
EA201890754A1 (ru) Соединения и способы их применения
EA201590997A1 (ru) Соединения и способы их применения
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
BR112018075166A2 (pt) derivados de carbonucleosídeo substituídos úteis como agentes anticâncer
CY1122243T1 (el) Παραγωγα ν-πυριδiνυλικoυ ακεταμιδιου ως αναστολεις της οδου σηματοδοτησης wnt
MX2015011752A (es) Metodos para tratar cancer de pulmon.
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
EA201892745A1 (ru) Фосфорамидатные производные нуклеозида в качестве противораковых агентов
EA201690785A1 (ru) Новая комбинированная терапия острого миелоидного лейкоза (омл)
EA201892769A3 (ru) Сложные диэфиры ациклических нуклеозидфосфонатов
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
CO6781549A2 (es) Uso de ligandos sigma en dolor por cáncer de huesos
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
EA201792287A1 (ru) Способы лечения рака
EA201792286A1 (ru) Способы лечения рака
EA201700286A1 (ru) Макромолекулярные комплексы переходного металла для лечения рака и способ их получения
RU2014145887A (ru) Комбинированная терапия с использованием антител против mif и химиотерапевтических средств
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
RU2014120179A (ru) Терапевтическая комбинация для лечения рака